by John R. Fischer
, Senior Reporter | March 29, 2021
Molecular Targeting Technologies Inc. (MTTI), a biopharmaceutical company, will supply Isotopia Molecular Imaging with no-carrier-added 177Lu (n.c.a. 177Lu ).
The supply will support clinical development of MTTI's products, 177Lu-EBTATE, for targeting somatostatin receptors type 2 in a variety of neuroendocrine tumors (NETs); and 177Lu-EBRGD, for integrin expressing cancers in glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC).
"We've secured a timely and sustainable supply of a key therapeutic ingredient needed for the development and launch of our lead asset 177Lu-EBTATE and other EB platform technologies,” said Dr. Chris Pak, president and CEO of MTTI, in a statement.
177Lu is designed to precisely destroy tumors when bound to disease-specific, targeting therapeutics and can penetrate soft tissue at a maximum of one millimeter from its binding site. It is covered by the NIH's Evans Blue Platform technology patents. The EB helps boost 177Lu's half-life of 6.7 days and delivers a high dosage to the targeted tumor.
Isotopia uses a unique, stable GMP method to produce a highly pure form of 177Lu. n.c.a. and eliminates cost-intensive clinical waste management.
MTTI plans to sell it through an exclusive NIH worldwide license.
"Our strategy is to be a partner to every leading pharmaceutical company developing Lu-177 n.c.a.-based products, supporting them from clinical trials through commercial sale. We are committed to produce 52 weeks per year, ensuring supply through long-term contracts,” said Isotopia's CEO Dr. Eli Shalom.